Jazz Pharmaceuticals submits FDA application for leukaemia treatment

Jazz Pharmaceuticals completed a rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of Vyxeos (cytarabine and daunorubicin) liposome for injection.

Spotlight

Spotlight

Related News